Halozyme Therapeutics (HALO) risk factors
Item 1A of every Halozyme Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors35 risks3 new5 reworded
Halozyme faces heightened exposure to federal pricing policy shifts, drug/device combination product regulations, and manufacturing disruptions. Executive actions and potential federal workforce reductions now pose specific risks to business operations and device growth.
Filed Feb 17, 2026 - FY2024 10-K risk factors32 risks
Halozyme relies heavily on its ENHANZE technology, the rHuPH20 enzyme, and key commercial partners for revenue. Significant long-term debt and convertible notes create substantial liquidity and conversion risks. The business faces rigorous regulatory oversight, drug-device combination complexities, and intense pharmaceutical competition.
Filed Feb 18, 2025